Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 5/20 | 0.50 |
| ▸ | RAB9A | P51151 | 5/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.50 |
| ▸ | CFTR | P13569 | 1/20 | 0.50 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | NAMPT | P43490 | 2/20 | 0.47 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL753183 | 1.00 | FDPS (0.51) | FDPSNPC1RAB9APKMCFTR | |
| SCHEMBL2159076 | 1.00 | FDPS (0.51) | FDPSNPC1RAB9APKMCFTR | |
| SCHEMBL8913509 | 0.87 | FDPS (0.51) | FDPSNPC1RAB9APKMCFTR | |
| SCHEMBL890100 | 0.87 | FDPS (0.51) | FDPSNPC1RAB9APKMCFTR | |
| SCHEMBL503440 | 0.83 | FDPS (0.54) | FDPSNPC1RAB9APKMCFTR | |
| SCHEMBL44078 | 0.83 | FDPS (0.54) | FDPSNPC1RAB9APKMCFTR | |
| SCHEMBL29417369 | 0.83 | FDPS (0.54) | FDPSNPC1RAB9APKMCFTR | |
| SCHEMBL44077 | 0.83 | FDPS (0.54) | FDPSNPC1RAB9APKMCFTR | |
| SCHEMBL8908911 | 0.83 | NPC1 (0.49) | FDPSNPC1RAB9APKMHTT | |
| SCHEMBL19364701 | 0.83 | FDPS (0.48) | FDPSNPC1RAB9APKMCFTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170320833-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-09 | — | — | US | disclosed |
| US-9758487-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-12 | — | — | US | disclosed |
| US-20160311778-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2016-10-27 | — | — | US | disclosed |
| EP-2471774-B1 | Piperidinyl derivatives as modulators of chemokine receptor activity | BRISTOL MYERS SQUIBB CO (US) | 2016-08-24 | — | — | EP | disclosed |
| US-9421192-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-08-23 | — | — | US | disclosed |
| US-20160067223-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-03-10 | — | — | US | disclosed |
| US-9227961-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-01-05 | — | — | US | disclosed |
| US-20150011754-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-01-08 | — | — | US | disclosed |
| US-8900566-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-02 | — | — | US | disclosed |
| US-8846023-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| US-20100158862-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-06-24 | — | — | US | disclosed |
| CN-101600691-A | Acyclic derivatives as modulators of chemokine receptor activity | BRISTOL MYERS SQUIBB CO (US) | 2009-12-09 | — | — | CN | disclosed |
| US-20090298833-A1 | PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-03 | — | — | US | disclosed |
| CN-101558059-A | Hepatitis C virus inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2009-10-14 | — | — | CN | disclosed |
| US-7601844-B2 | Piperidinyl derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-13 | — | — | US | disclosed |
| EP-2049486-A2 | PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Company (US) | 2009-04-22 | — | — | EP | disclosed |
| US-20090068140-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-03-12 | — | — | US | disclosed |
| US-20080050336-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-28 | — | — | US | disclosed |
| US-20070208056-A1 | PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2007-09-06 | — | — | US | disclosed |
| WO-2007092681-A2 | PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160067223-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | FDPS 546/4885NPC1 65/4885RAB9A 2463/4885 |
| US-20090298833-A1 | PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCR1, CCR2, CCR3 | FDPS 3363/4885NPC1 1547/4885RAB9A 855/4885 |
| US-20080050336-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | FDPS 546/4885NPC1 65/4885RAB9A 2463/4885 |
| US-20090068140-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | FDPS 546/4885NPC1 65/4885RAB9A 2463/4885 |
| US-20070208056-A1 | PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCR1, CCR2, CCR3 | FDPS 3363/4885NPC1 1547/4885RAB9A 855/4885 |
| US-20170320833-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | FDPS 546/4885NPC1 65/4885RAB9A 2463/4885 |
| US-20150011754-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | FDPS 546/4885NPC1 65/4885RAB9A 2463/4885 |
| US-20160311778-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | FDPS 546/4885NPC1 65/4885RAB9A 2463/4885 |
| US-20100158862-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | FDPS 546/4885NPC1 65/4885RAB9A 2463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.